论文部分内容阅读
第三代头孢菌素大多于20世纪70～80年代开发,90年代后广泛用于临床。虽然目前头孢菌素已发展至第四代,但由于第三代的抗菌活性强,抗菌谱广,且性能稳定,作用时间长,不良反应及毒性较低,故受到广泛欢迎。目前,用于临床的第三代头孢菌素达10多个品种,如头孢噻肟钠、头孢哌酮钠、头孢他啶、头孢曲松等。但因其可以引起患者凝血功能障碍,从而导致出血的报道近年逐渐增多,给患者
The third-generation cephalosporins were mostly developed in the 1970s and 1980s and widely used in the clinic after the 1990s. Although cephalosporins have been developed to the fourth generation at present, the third generation has been widely welcomed due to its strong antibacterial activity, broad antibacterial spectrum, stable performance, long acting time, adverse reactions and low toxicity. At present, the third-generation cephalosporins used clinically for more than 10 varieties, such as cefotaxime sodium, cefoperazone sodium, ceftazidime, ceftriaxone and so on. But because it can cause coagulation disorders in patients, resulting in reports of bleeding gradually increased in recent years, to patients